Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01083615 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Phase 3 study, sponsored by Achieve Life Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 14
- Enrollment target
NCT01083615: Clinical Trial Phase 3 study, sponsored by Achieve Life Sciences.
NCT01083615 is a Phase 3 study that was terminated before completion, run by Achieve Life Sciences. The registered enrollment target is 14 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01083615, a Phase 3 study, was terminated before completion, sponsored by Achieve Life Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the addition of study drug (custirsen) can provide durable pain palliation for castrate resistant prostate cancer patients receiving docetaxel retreatment or cabazitaxel as a second line therapy.
Interventions
- DRUG prednisone
- DRUG docetaxel
- DRUG custirsen sodium
- DRUG cabazitaxel
- DRUG isotonic, 0.9% sodium chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-03 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Why NCT01083615 stopped before completion
NCT01083615 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT01083615 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01083615 about?
NCT01083615 is a clinical study titled "A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)". The purpose of this study is to determine if the addition of study drug (custirsen) can provide durable pain palliation for castrate resistant prostate cancer patients receiving docetaxel retreatment or cabazitaxel as a second line therapy.
What is the current status of trial NCT01083615?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 14 participants. The study started on 2010-03. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01083615?
The interventions under investigation include: prednisone (DRUG), docetaxel (DRUG), custirsen sodium (DRUG), cabazitaxel (DRUG), isotonic, 0.9% sodium chloride (DRUG).
Who is sponsoring clinical trial NCT01083615?
This trial is sponsored by Achieve Life Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01083615's enrollment target sits among peer trials
14 1983rd of 2000 higher than 17 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia